2019-07-11 Introduced in Senate Affordable Insulin Approvals Now Act

This bill requires the continued review and approval, as appropriate, of certain pending applications for generic insulin beyond the March 23, 2020, cutoff date previously established by the Food and Drug Administration. Beginning March 23, 2020, these approved generic insulin drugs also are deemed licensed biological products.

]]>

text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.